title: The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.
abstract: The genetic predisposition to a long-term efficacy of anti-tumor necrosis factor (TNF)α treatment in seronegative spondyloarthritis (SpA) was investigated by analysing the possible correlation between several single nucleotide gene polymorphisms and the retention rate of anti-TNFα therapies. We compared patients needing to switch the first anti-TNFα (Sw, No. 64) within at least 12 months of follow-up with patients not needing to switch (NSw, No. 123), observing at least 6 months of treatment to establish anti-TNFα failure, leading to treatment change. Response to treatment was evaluated by standardised criteria (BASDAI for axial involvement, DAS28-EULAR for peripheral involvement). The TNFα -308 A allele and the interleukin (IL)-6 -174GG homozygosis resulted as independent biomarkers predicting survival of the first anti-TNFα therapy in SpA patients (P=0.007, odds ratio (OR): 4.4, 95% confidence interval (CI)=1.5-13.1 and P=0.035, OR: 2.1, 95% CI=1.1-4.4). Also, the male gender (P=0.001, OR: 3.4, 95% CI=1.6-7.1) associated with the NSw phenotype, whereas no association was found either with the specific diagnosis or the predominant joint involvement.
authors.affiliation: Clinical Pathology, University-Hospital of Udine, Udine, Italy.|Department of Medical and Biological Sciences, University of Udine, Udine, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Fabris
authors.affiliation: Department of Medical and Biological Sciences, University of Udine, Udine, Italy.|Rheumatology, University-Hospital of Udine, Udine, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Quartuccio
authors.affiliation: Rheumatology, University-Hospital of Udine, Udine, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Fabro
authors.affiliation: Rheumatology, University-Hospital of Udine, Udine, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Sacco
authors.affiliation: Institute of Physical Medicine and Rehabilitation 'Gervasutta', Udine, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Lombardi
authors.affiliation: Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Ramonda
authors.affiliation: Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Biasi
authors.affiliation: Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Punzi
authors.affiliation: Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.affiliation: Rheumatology Department of Lucania, San Carlo Hospital of Potenza, Potenza, Italy.
authors.forename: I
authors.initials: I
authors.lastname: Olivieri
authors.affiliation: Clinical Pathology, University-Hospital of Udine, Udine, Italy.|Department of Medical and Biological Sciences, University of Udine, Udine, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Curcio
authors.affiliation: Department of Medical and Biological Sciences, University of Udine, Udine, Italy.|Rheumatology, University-Hospital of Udine, Udine, Italy.
authors.forename: S
authors.initials: S
authors.lastname: De Vita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D057915:Drug Substitution; D005260:Female; D056726:Genetic Association Studies; D006720:Homozygote; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics*; D007558:Italy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D000071185:Pharmacogenomic Testing; D000071184:Pharmacogenomic Variants / Q000235:genetics*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D011401:Promoter Regions, Genetic; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D025241:Spondylarthritis / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D013997:Time Factors; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000276:immunology; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; C508600:IL6 protein, human; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha